Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity

Next Previous
Trial Profile

A Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATR 04 (Primary)
  • Indications Exanthema
  • Focus Adverse reactions; First in man
  • Sponsors Azitra

Most Recent Events

  • 14 May 2025 According to an Azitra media release, the company will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor (EGFRi)-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
  • 25 Apr 2025 Status changed from not yet recruiting to recruiting as per Azitra media release
  • 25 Apr 2025 According to an Azitra media release, abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top